SEARCH

SEARCH BY CITATION

References

  • Azzato, E.M., Greenberg, D., Shah, M., Blows, F., Driver, K.E., Caporaso, N.E., and Pharoah, P.D. (2009). Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br. J. Cancer 100, 18061811.
  • Azzato, E.M., Pharoah, P.D., Harrington, P. et al. (2010). A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol. Biomarkers Prev. 19, 11401143.
  • Balch, C.M., Soong, S.J., Gershenwald, J.E. et al. (2001). Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 36223634.
  • Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2010). Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J. Clin. Oncol. 28, 24522459.
  • Beaumont, K.A., Shekar, S.N., Cook, A.L., Duffy, D.L., and Sturm, R.A. (2008). Red hair is the null phenotype of MC1R. Hum. Mutat. 29, E88E94.
  • Bishop, D.T., Demenais, F., Iles, M.M. et al. (2009). Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41, 920925.
  • Brown, K.M., Macgregor, S., Montgomery, G.W. et al. (2008). Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40, 838840.
  • Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 34263439.
  • Cnaan, A., and Ryan, L. (1989). Survival analysis in natural history studies of disease. Stat. Med. 8, 12551268.
  • Crocetti, E., and Carli, P. (2003). Changes from mid-1980s to late 1990s among clinical and demographic correlates of melanoma thickness. Eur. J. Dermatol. 13, 7275.
  • Cuellar, F., Puig, S., Kolm, I., Puig-Butille, J., Zaballos, P., Marti-Laborda, R., Badenas, C., and Malvehy, J. (2009). Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers. Br. J. Dermatol. 160, 4853.
  • Demenais, F., Mohamdi, H., Chaudru, V. et al. (2010). Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J. Natl Cancer Inst. 102, 15681583.
  • Du, J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., Ross, K., Huber, W.E., Nishimura, E.K., Golub, T.R., and Fisher, D.E. (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565576.
  • Duffy, D.L., Box, N.F., Chen, W., Palmer, J.S., Montgomery, G.W., James, M.R., Hayward, N.K., Martin, N.G., and Sturm, R.A. (2004). Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum. Mol. Genet. 13, 447461.
  • Falchi, M., Bataille, V., Hayward, N.K. et al. (2009). Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915919.
  • Fargnoli, M.C., Pike, K., Pfeiffer, R.M. et al. (2008). MC1R variants increase risk of melanomas harboring BRAF mutations. J. Invest. Dermatol. 128, 24852490.
  • Gandini, S., Sera, F., Cattaruzza, M.S., Pasquini, P., Abeni, D., Boyle, P., and Melchi, C.F. (2005a). Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur. J. Cancer 41, 2844.
  • Gandini, S., Sera, F., Cattaruzza, M.S., Pasquini, P., Zanetti, R., Masini, C., Boyle, P., and Melchi, C.F. (2005b). Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur. J. Cancer 41, 20402059.
  • Garbe, C., McLeod, G.R., and Buettner, P.G. (2000). Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 89, 12691278.
  • Ghiorzo, P., Pastorino, L., Pizzichetta, M.A. et al. (2009). CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Res. 19, 142145.
  • Goldstein, A.M., Chaudru, V., Ghiorzo, P. et al. (2007). Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int. J. Cancer 121, 825831.
  • Gudbjartsson, D.F., Sulem, P., Stacey, S.N. et al. (2008). ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886891.
  • Guedj, M., Bourillon, A., Combadieres, C. et al. (2008). Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum. Mutat. 29, 11541160.
  • Hacker, E., Hayward, N.K., Dumenil, T., James, M.R., and Whiteman, D.C. (2010). The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J. Invest. Dermatol. 130, 241248.
  • Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646674.
  • Harland, M., Goldstein, A.M., Kukalizch, K. et al. (2008). A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur. J. Cancer 44, 12691274.
  • Hoiom, V., Tuominen, R., Kaller, M., Linden, D., Ahmadian, A., Mansson-Brahme, E., Egyhazi, S., Sjoberg, K., Lundeberg, J., and Hansson, J. (2009). MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res. 22, 196204.
  • Horgan, A.M., Yang, B., Azad, A.K., Amir, E., John, T., Cescon, D.W., Wheatley-Price, P., Hung, R.J., Shepherd, F.A., and Liu, G. (2011). Pharmacogenetic and germline prognostic markers of lung cancer. J. Thorac. Oncol. 6, 296304.
  • Jewell, R., Conway, C., Mitra, A. et al. (2010). Patterns of expression of DNA repair genes and relapse from melanoma. Clin. Cancer Res. 16, 52115221.
  • Kadekaro, A.L., Leachman, S., Kavanagh, R.J. et al. (2010). Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J. 24, 38503860.
  • Kaller, M., Tuominen, R., Ahmadian, A., Magnusson, V., Egyhazi, S., Hansson, J., and Lundeberg, J. (2005). Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing. Clin. Chem. 51, 23882391.
  • Kanetsky, P.A., Ge, F., Najarian, D., Swoyer, J., Panossian, S., Schuchter, L., Holmes, R., Guerry, D., and Rebbeck, T.R. (2004). Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. Cancer Epidemiol. Biomarkers Prev. 13, 808819.
  • Kanetsky, P.A., Panossian, S., Elder, D.E., Guerry, D., Ming, M.E., Schuchter, L., and Rebbeck, T.R. (2010). Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer 116, 24162428.
  • Landi, M.T., Bauer, J., Pfeiffer, R.M., Elder, D.E., Hulley, B., Minghetti, P., Calista, D., Kanetsky, P.A., Pinkel, D., and Bastian, B.C. (2006). MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313, 521522.
  • Lee, T.K., Rivers, J.K., and Gallagher, R.P. (2005). Site-specific protective effect of broad-spectrum sunscreen on nevus development among white schoolchildren in a randomized trial. J. Am. Acad. Dermatol. 52, 786792.
  • Lipsker, D., Engel, F., Cribier, B., Velten, M., and Hedelin, G. (2007). Trends in melanoma epidemiology suggest three different types of melanoma. Br. J. Dermatol. 157, 338343.
  • Liu, F., Fu, Y., and Meyskens, F.L., Jr. (2009). MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J. Invest. Dermatol. 129, 422431.
  • Loercher, A.E., Tank, E.M., Delston, R.B., and Harbour, J.W. (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 3540.
  • Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 12391246.
  • Matichard, E., Verpillat, P., Meziani, R. et al. (2004). Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J. Med. Genet. 41, e13.
  • McGill, G.G., Horstmann, M., Widlund, H.R. et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707718.
  • Pastorino, L., Bonelli, L., Ghiorzo, P. et al. (2008). CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res. 21, 700709.
  • R Development Core Team (2009). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
  • Randerson-Moor, J.A., Taylor, J.C., Elliott, F. et al. (2009). Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur. J. Cancer 45, 32713281.
  • Robinson, S., Dixon, S., August, S., Diffey, B., Wakamatsu, K., Ito, S., Friedmann, P.S., and Healy, E. (2010). Protection against UVR involves MC1R-mediated non-pigmentary and pigmentary mechanisms in vivo. J. Invest. Dermatol. 130, 19041913.
  • Sarasin, A., and Kauffmann, A. (2008). Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat. Res. 659, 4955.
  • Scherer, D., Nagore, E., Bermejo, J.L., Figl, A., Botella-Estrada, R., Thirumaran, R.K., Angelini, S., Hemminki, K., Schadendorf, D., and Kumar, R. (2009). Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int. J. Cancer 125, 18681875.
  • Si, L., Kong, Y., Xu, X., Flaherty, K.T., Sheng, X., Cui, C., Chi, Z., Li, S., Mao, L., and Guo, J. (2012). Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer 48, 94100.
  • Song, X., Mosby, N., Yang, J., Xu, A., Abdel-Malek, Z., and Kadekaro, A.L. (2009). alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res. 22, 809818.
  • Thomas, N.E., Kanetsky, P.A., Edmiston, S.N. et al. (2010). Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. J. Invest. Dermatol. 130, 14631465.
  • Valverde, P., Healy, E., Jackson, I., Rees, J.L., and Thody, A.J. (1995). Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat. Genet. 11, 328330.
  • Winnepenninckx, V., Lazar, V., Michiels, S. et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 98, 472482.
  • Wu, C., Xu, B., Yuan, P. et al. (2010). Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res. 70, 97219729.
  • Yang, S., Irani, K., Heffron, S.E., Jurnak, F., and Meyskens, F.L., Jr. (2005). lterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 4, 19231935.